Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

FDA to Amarin: No Appeal for You
Motley Fool
Saturday, November 23, 2013 - 12:47pm
tags:
FDA, Amarin, Vascepa
Pfizer Feels the Heat From Novartis
Wall St Cheat Sheet
Saturday, November 23, 2013 - 12:45pm
tags:
Pfizer, Novartis, breast cancer, LEE011, palbociclib
Update on Glaxo-Amicus Deal
Yahoo/Zacks
Saturday, November 23, 2013 - 12:44pm
tags:
GSK, Amicus Therapeutics, Migalastat HCl, Fabry's disease
Regeneron's Eylea Approved by Japanese Regulator
Motley Fool
Saturday, November 23, 2013 - 12:40pm
tags:
Regeneron, Eylea, macular edema
Stemline Therapeutics Announces the Presentation of Clinical Trial Results With a Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Society of Neuro-Oncology (SNO) Annual Meeting
Yahoo/Globe Newswire
Saturday, November 23, 2013 - 12:37pm
tags:
SL-701, brain cancer, Stemline Therapeutics
The Four Horseman of Pharma
CNBC
Saturday, November 23, 2013 - 12:36pm
tags:
Gilead, Biogen Idec, Celgene, Regeneron
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Yahoo/PR NewsWire
Saturday, November 23, 2013 - 12:06pm
tags:
Nexavar, Bayer, ONYX Pharmaceuticals, Amgen, thyroid cancer, refractory differential thyroid cancer
U.S. judge throws out SEC lawsuit over 'suspicious' Onyx trading
Yahoo/Reuters
Saturday, November 23, 2013 - 12:04pm
tags:
ONYX Pharmaceuticals, SEC, lawsuits
DaVita Spared as Medicare Wipes Out 9.4% Dialysis Cut
Bloomberg
Saturday, November 23, 2013 - 12:00pm
tags:
DaVita, dialysis, Medicare
Ariad jumps as company says EU regulators may be willing to keep its cancer drug on the market
Yahoo/AP
Friday, November 22, 2013 - 11:42am
tags:
Europe, Iclusig, Ariad Pharmaceuticals
Food allergy startup bags $17M for oral immunotherapy
Fierce Biotech
Friday, November 22, 2013 - 11:04am
tags:
food allergies, Allergen Research Corp
J&J Said to Narrow Bidder List to 3 for Diagnostics Business
Bloomberg
Friday, November 22, 2013 - 11:01am
tags:
JNJ, M&A, diagnostics, Ortho Clinical Diagnostics
Novartis Sets $5 Billion Buyback, Adds Business Segments
Bloomberg
Friday, November 22, 2013 - 10:59am
tags:
Novartis, share repurchase, dermatology, heart failure, respiratory health, cell therapy
A Closer Look At Neuralstem's ALS Treatment
Forbes
Friday, November 22, 2013 - 10:33am
tags:
Neuralstem, ALS, amyotrophic lateral sclerosis
Cyberonics soars on a strong Q2 results, record sales, boosted guidance
Mass Device
Friday, November 22, 2013 - 10:30am
tags:
earnings, devices, Cyberonics
Sam Waksal, A Hepatitis C Medicine And An FDA Warning Letter
Pharmalot
Friday, November 22, 2013 - 10:28am
tags:
hepatitis C, FDA, Ribasphere, Kadmon
Novartis chases Pfizer in hot new breast cancer drug area
Yahoo/Reuters
Friday, November 22, 2013 - 10:27am
tags:
Pfizer, breast cancer, Novartis
Amarin faces another setback on expanded use of its lead drug
Yahoo/Reuters
Friday, November 22, 2013 - 10:24am
tags:
Amarin, Vascepa
Glaxo, Pfizer's HIV Treatment Recommended by EU Regulator
Bloomberg
Friday, November 22, 2013 - 10:22am
tags:
GSK, Pfizer, HIV, Europe, Tivicay
Keep an Eye on Pacific Biosciences, Epizyme, and Merrimack Today
Motley Fool
Friday, November 22, 2013 - 10:21am
tags:
Pacific Biosciences, Epizyme, Merrimack Pharmaceuticals

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.